Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorBOUAZZA, Naim
dc.contributor.authorSEMERARO, Michaela
dc.contributor.authorLUI, Gabrielle
dc.contributor.authorFROELICHER-BOURNAUD, Leo
dc.contributor.authorCHOUPEAUX, Laure
dc.contributor.authorTRELUYER, Jean-Marc
dc.contributor.authorBENABOUD, Sihem
dc.contributor.authorTERZIC, Joelle
dc.contributor.authorHACHULLA, Eric
dc.contributor.authorREMY, Philippe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
dc.contributor.authorKARRAS, Alexandre
dc.contributor.authorROUSSET-ROUVIERE, Caroline
dc.contributor.authorJOLIVOT, Anne
dc.contributor.authorAMOURA, Zahir
dc.contributor.authorDAUGAS, Eric
dc.contributor.authorHUMMEL, Aurelie
dc.contributor.authorSALOMON, Remi
dc.contributor.authorLEGA, Jean-Christophe
dc.contributor.authorDECRAMER, Stephane
dc.contributor.authorBELOT, Alexandre
dc.contributor.authorGOBERT, Delphine
dc.contributor.authorCOSTEDOAT-CHALUMEAU, Nathalie
dc.contributor.authorFAGUER, Stanislas
dc.contributor.authorMELKI, Isabelle
dc.contributor.authorJOURDE-CHICHE, Noemie
dc.contributor.authorBADER-MEUNIER, Brigitte
dc.date.accessioned2025-07-04T14:37:48Z
dc.date.available2025-07-04T14:37:48Z
dc.date.issued2025-05-23
dc.identifier.issn1365-2125en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207222
dc.description.abstractEnAimsPrednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE) to forecast free prednisolone concentrations and its association with disease activity.MethodsA total of 66 active SLE patients (adults and children) were included, and followed up prospectively (242 observations available). Plasma prednisolone concentrations were assessed using liquid chromatography-mass spectrometry, and the data were analysed using Monolix software. The pharmacokinetic model was a one-compartment open model with absorption lag time representing the delay for both absorption and metabolism from inactive (prednisone) to active form (prednisolone). This model predicted free concentrations, which were then used to calculate total concentrations based on established binding constants.ResultsFree prednisolone clearance (CLu/F) and volume of distribution (Vu/F) were scaled allometrically to body weight. The typical population estimates (95% confidence interval) were 54 (48-62) L/h/70 kg and 235 (203-274) L/70 kg, respectively. Additionally, the bioavailability parameter was found to decrease non-linearly with the dose. Prednisolone cumulative exposure was not different between patients who responded at 3 months and those who did not.ConclusionsRobust pharmacokinetic targets are not yet clearly defined regarding toxicity or efficacy and are warranted in order to make a valuable contribution to prednisolone therapeutic drug monitoring in the context of SLE.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enDisease Activity
dc.subject.enPopulation Pharmacokinetics
dc.title.enPopulation pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity
dc.title.alternativeBr J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/bcp.70103en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAssistance publique-Hôpitaux de Parisen_US
hal.identifierhal-05144962
hal.version1
hal.date.transferred2025-07-04T14:37:52Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2025-05-23&rft.eissn=1365-2125&rft.issn=1365-2125&rft.au=BOUAZZA,%20Naim&SEMERARO,%20Michaela&LUI,%20Gabrielle&FROELICHER-BOURNAUD,%20Leo&CHOUPEAUX,%20Laure&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record